Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Polycythemia Vera 2Primary Myelofibrosis 1

Interventions

Cyclophosphamide 36fludarabine phosphate 32Tacrolimus 28Busulfan 24Peripheral Blood Stem Cell Transplantation 23Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 18Methotrexate 16fludarabine 14ruxolitinib 13Melphalan 12Cyclosporine 12thymoglobulin 8Stem Cell Transplantation 8Radiotherapy 8Methylprednisolone 8Sirolimus 6Prednisone 6Cord Blood Stem Cell Transplantation 6Specimen Handling 5Filgrastim 5Etoposide 5Alemtuzumab 5merphos 4itacitinib 4Imatinib Mesylate 4INCB039110 4Hematopoietic Stem Cell Transplantation 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Primary Myelofibrosis × bomedemstat × Clear all
NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡